Lyme Disease Diagnosis and Treatment: Rash, Arthritis, Carditis and Neurologic Lyme

Evidence reviewed: 8 November 2026. Lyme disease is a tickborne infection caused by Borrelia burgdorferi and related Borrelia species. It can affect skin, joints, the nervous system and heart, but its manifestations and diagnostic tests vary with the stage of infection. A typical expanding erythema migrans (EM) rash in a person with plausible endemic exposure is usually diagnosed clinically and treated without waiting for antibody tests. For other manifestations, the CDC’s November 2, 2026 guidance recommends an FDA-cleared two-tier antibody testing strategy, interpreted alongside symptoms and exposure history. Antibiotic choice and duration depend on the clinical manifestation; unnecessarily prolonged antibiotic courses are not recommended for nonspecific symptoms after adequate treatment [1–4].

How Lyme disease develops

Lyme disease follows exposure to an infected Ixodes (blacklegged) tick, with transmission risk influenced by tick species, geography and attachment duration. After infection, bacteria may first cause a localized expanding rash; untreated infection can sometimes disseminate and produce multiple skin lesions, facial palsy, meningitis, cardiac conduction abnormalities or later arthritis. Not every person develops each stage, and the absence of a recalled tick bite does not exclude Lyme disease [1,2].

Geographic context is essential. Lyme is endemic in particular regions of North America, Europe and Asia; a positive antibody test without relevant exposure or compatible findings may reflect a false positive or past infection. Symptoms such as fatigue, headache and joint pain are nonspecific and should not automatically be diagnosed as Lyme.

Clinical manifestations

Manifestation Typical features Diagnostic implication
Early localized disease Expanding erythema migrans, possible fatigue, headache, fever and aches. Typical EM plus endemic exposure generally warrants clinical diagnosis and prompt antibiotics.
Early disseminated disease Multiple EM lesions, facial nerve palsy, meningitis, radicular pain or carditis. Clinical assessment, targeted tests and organ-specific management.
Lyme carditis Palpitations, chest pain, shortness of breath, dizziness, syncope or conduction block. ECG and urgent evaluation when clinically suspected.
Lyme arthritis Intermittent or persistent swelling of one or a few large joints, especially the knee. Two-tier serology is usually positive in late Lyme arthritis.
Post-treatment symptoms Persistent fatigue, pain or cognitive complaints after appropriately treated infection. Reassess alternative causes and function; do not infer active infection from antibodies alone.

Erythema migrans: the rash is not always a bull’s-eye

EM generally appears days to weeks after infection and expands gradually. Although sometimes described as a circular “bull’s-eye,” it may be uniformly colored, oval or irregular without central clearing. Skin inflammation may look different on darker skin. A small area of redness immediately following a tick bite may represent a local reaction rather than EM [1].

The CDC’s March 2026 clinical guidance stresses that patients with a typical EM rash and possible tick exposure in an endemic area should be treated promptly even if early antibody testing is negative [1].

Why Lyme blood tests can be negative early

Most Lyme tests measure antibodies, which develop over time. The CDC states that serology may be falsely negative during the first 4–6 weeks. Therefore, a negative test taken soon after a bite does not exclude a typical early Lyme presentation [2].

Conversely, antibodies can remain elevated for months to years after successful treatment; this means a positive test does not necessarily prove active ongoing infection, nor should serial antibody titers be used to determine cure [2].

CDC two-tier serologic testing in 2026

The recommended approach is two-step testing using FDA-cleared assays. Standard testing uses an enzyme immunoassay (EIA) followed by an immunoblot when the first assay is positive or equivocal. Modified two-tier testing uses two appropriately cleared EIAs instead of an immunoblot [2].

  1. Assess clinical probability: epidemiologic exposure, rash, neurological/cardiac or joint findings and alternative diagnoses.
  2. Order an FDA-cleared first-tier assay when laboratory confirmation is appropriate.
  3. Complete the recommended second tier if the first is positive or equivocal.
  4. Interpret both together rather than treating a single isolated band or unvalidated laboratory result as proof.
  5. If early infection remains possible despite negative serology, repeat testing may be appropriate later according to symptoms, timing and the clinical pathway.

CDC advises that a positive IgM immunoblot should generally be disregarded when symptoms have lasted more than 30 days, because false positive IgM results are more likely in that setting. Antibody testing is not a test of treatment response [2].

When not to test for Lyme disease

Testing is generally not recommended in an asymptomatic person after an uncomplicated tick bite or in people with low-pretest-probability symptoms and no exposure evidence. The IDSA/AAN/ACR guideline recommends against routine Lyme testing solely because of nonspecific psychiatric symptoms or developmental/behavioral disorders without appropriate epidemiologic and clinical features [3].

False-positive results can lead to inappropriate antibiotics and missed diagnoses. Clinical judgment matters as much as which assay is used.

Treatment of early localized Lyme disease

The 2020 IDSA/AAN/ACR guideline and 2026 CDC guidance recommend oral antibiotics for typical EM. Common adult regimens are doxycycline for 10 days, or amoxicillin or cefuroxime axetil for 14 days, with age-, pregnancy- and allergy-related adjustments [1,3].

Medicine Typical role in early EM Important precautions
Doxycycline Often first-choice oral therapy in eligible patients; 10-day course for uncomplicated EM. Photosensitivity, esophageal irritation and pregnancy considerations; take as directed and review interactions.
Amoxicillin Effective alternative; typically 14 days for EM. Penicillin allergy, renal considerations and dose adjustment for age/weight.
Cefuroxime axetil Effective alternative; typically 14 days for EM. Cephalosporin allergy, administration instructions and renal considerations.
Azithromycin Generally reserved for selected patients unable to use preferred oral options. Less preferred, different duration and potential cardiac/drug interactions.

These are guideline examples, not individual prescriptions. Children, pregnant patients and those with drug allergies or organ impairment require individualized regimens. One prophylactic doxycycline dose is not adequate treatment for established EM.

Lyme disease in pregnancy

Suspected Lyme disease during pregnancy requires prompt evaluation because untreated infection can affect maternal health. For uncomplicated EM, amoxicillin or cefuroxime are commonly used options; doxycycline is often avoided or carefully reviewed according to clinical circumstances. Severe disease can require inpatient treatment and specialist advice [1,3].

Patients who are pregnant should not self-select antibiotics based on a generic adult table. Appropriate treatment is generally effective, and decisions depend on manifestation, allergy history and gestational circumstances.

Neurologic Lyme disease: facial palsy, meningitis and radiculopathy

Lyme neuroborreliosis may produce facial nerve palsy, meningitis, painful nerve-root inflammation or other neurological symptoms. These findings can overlap with serious alternative diagnoses, especially stroke, other meningitides and Bell’s palsy. New facial weakness, severe headache with neck stiffness or progressive neurological symptoms require urgent assessment [3].

For Lyme-associated meningitis, cranial neuropathy or peripheral nervous-system involvement without parenchymal brain/spinal cord involvement, IDSA/AAN/ACR recommends intravenous ceftriaxone, cefotaxime or penicillin G, or oral doxycycline in suitable patients, with a typical duration of 14–21 days. Route depends on severity, ability to take oral treatment and other factors. Parenchymal brain or spinal cord disease generally favors intravenous therapy [3].

There is no recommendation to give corticosteroids routinely as adjuncts for confirmed Lyme facial nerve palsy because evidence is insufficient; the decision differs from idiopathic Bell’s palsy and merits appropriate expert assessment.

Lyme carditis and heart block

Lyme carditis can disturb cardiac conduction, sometimes producing varying degrees of atrioventricular (AV) block. Warning symptoms include palpitations, chest discomfort, breathlessness, fainting or near-fainting after possible tick exposure [3].

ECG is recommended for patients with signs or symptoms suggestive of carditis, not automatically for everyone with a simple EM rash. Severe conduction disease may require hospital admission, cardiac monitoring and intravenous ceftriaxone, with step-down to oral treatment after improvement. The usual total antibiotic duration is 14–21 days in guideline pathways [3].

Fainting, persistent chest pain or new serious palpitations are emergencies, whether or not Lyme is eventually the cause.

Lyme arthritis

Lyme arthritis typically causes swelling of one or a few large joints, most notably the knee, weeks or months after infection. Pain may be less dramatic than visible swelling. Diagnosis uses serum antibody testing in compatible cases; when added evidence is necessary in seropositive individuals, synovial-fluid PCR may be considered [3].

The IDSA/AAN/ACR guideline recommends an initial 28-day oral antibiotic course for Lyme arthritis. After treatment, management depends on response; some patients with persistent synovitis may need another targeted regimen or specialist assessment, while others have postinfectious immune-mediated joint inflammation rather than ongoing infection [3].

Never assume a swollen knee is Lyme disease. Septic arthritis, crystal disease and other inflammatory conditions can be urgent and need appropriate evaluation.

What are post-treatment Lyme disease symptoms?

Some people experience fatigue, pain, cognitive complaints or sleep problems after completing recommended treatment, even without objective signs of active infection. The CDC acknowledges these prolonged symptoms and recommends a careful search for alternative or concurrent causes, supportive care and individualized follow-up [4].

The term post-treatment Lyme disease syndrome (PTLDS) may be used for selected patients with persistent symptoms after documented treated infection. However, the label should not be applied to unexplained fatigue without evidence of prior Lyme disease, and it does not prove that living Borrelia bacteria remain.

Why prolonged antibiotic treatment is not recommended routinely

For patients with persistent or recurrent nonspecific symptoms after guideline-recommended Lyme treatment but without objective evidence of reinfection or treatment failure, IDSA/AAN/ACR recommends against additional antibiotic therapy [3]. Clinical trials have not demonstrated reliable sustained benefit from prolonged repeated antibiotics for such symptoms, while risks include drug reactions, intravenous line infections and other serious complications.

This recommendation does not mean patients should be dismissed. Clinicians should take symptoms seriously, review function and sleep, examine for objective disease, and address treatable physical or psychological contributors.

Reinfection versus persistent antibodies

A person who has recovered from Lyme disease can be reinfected after a new infected tick bite. A new expanding EM rash with appropriate exposure may indicate new infection. Because antibodies can remain positive for years, a repeat positive antibody test by itself cannot distinguish old infection from reinfection [2,4].

Clinical history, new objective findings and exposure determine next steps. Additional antibiotics should not be prescribed solely to force antibody levels back to negative.

Practical prevention after a past infection

There is currently no licensed human Lyme disease vaccine routinely available in the United States. Prevention relies on EPA-registered tick repellents, permethrin-treated clothing, tick checks and prompt removal in endemic areas. A prior episode does not create reliable lifelong immunity [5].

Our Lyme early signs, tick removal and prophylaxis guide explains the 36-hour attachment and 72-hour prophylaxis assessment criteria in detail.

When should a specialist be involved?

Infectious disease, neurology, cardiology or rheumatology referral can be useful for atypical presentations, pregnancy with complex disease, heart block, meningitis, severe arthritis or persistent objectively abnormal findings. A patient’s treatment should reflect the specific manifestation rather than an unsupported formula based only on antibody titers.

Frequently asked questions

Should a classic EM rash wait for a positive Lyme blood test?

No. Early antibodies may be negative, so typical EM with exposure in an endemic area should be treated promptly [1,2].

Can antibodies stay positive after cure?

Yes. Antibodies often persist for months to years and should not be used to document treatment success [2].

Is every facial palsy caused by Lyme?

No. Several urgent neurological and infectious causes exist. Clinical context and appropriate assessment are essential.

Does Lyme arthritis always need intravenous antibiotics?

No. The recommended initial regimen is usually 28 days of oral antibiotics for confirmed Lyme arthritis [3].

Can Lyme disease cause heart block?

Yes. Carditis can impair conduction and requires urgent medical evaluation when symptoms are present.

Will months of additional antibiotics reliably cure post-treatment fatigue?

No. Guidelines advise against routine prolonged antibiotics without objective evidence of reinfection or treatment failure [3,4].

Key takeaways

Lyme disease testing and treatment depend on the manifestation. Treat a typical early expanding rash clinically; use validated two-tier serology for later or atypical presentations. Neurologic Lyme disease, carditis and arthritis require distinct regimens and sometimes urgent hospitalization. Persistent antibodies or nonspecific symptoms do not by themselves justify repeated antibiotics.

References

  1. Centers for Disease Control and Prevention. Clinical treatment of erythema migrans rash. 27 March 2026.
  2. Centers for Disease Control and Prevention. Clinical testing and diagnosis for Lyme disease. 2 November 2026.
  3. Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical practice guidelines by the IDSA, AAN and ACR for prevention, diagnosis and treatment of Lyme disease. Clin Infect Dis. 2021;72:e1–e48. Guideline.
  4. Centers for Disease Control and Prevention. Clinical care of Lyme disease and prolonged symptoms. Updated 2026.
  5. Centers for Disease Control and Prevention. Preventing Lyme disease. Updated 2026.

Medical disclaimer: Educational information only. Lyme diagnosis requires exposure assessment, validated testing where appropriate and clinician judgment. Sudden weakness, fainting, serious palpitations, chest pain or signs of meningitis demand urgent evaluation. Antibiotic courses must be individualized by a qualified professional.

Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *